ZoBio is a market leading supplier of an array of biophysical techniques to aid modern drug discovery efforts.
Established in 2004 in The Netherlands, ZoBio has provided innovative and reliable research services to customers across the pharmaceutical and biotechnology industries. ZoBio was founded as a spin-off company from Leiden University.
ZoBio is recognized for its breakthrough technology Targeted Immobilized NMR Screening. ZoBio has established and demonstrated the efficacy of Target Immobilized NMR Screening technology for the discovery of high quality, diverse fragment ligands for a variety of challenging targets including membrane bound proteins, such as GPCRs. In addition, orthogonal validation technologies such as SPR and protein observed NMR have now been implemented. Biophysical techniques such as NMR are utilized by ZoBio to rapidly identify the structure of target-small molecule complexes to reinforce Fragment and Structure based drug discovery.
By assimilating these technologies ZoBio has created an efficient pipeline to support hit to clinical candidate programs on targets unlike any other CRO.
Our clients currently include 7 of the top 15 pharma and other various mid-size pharmaceutical companies. Here are just a few of the organisations we are currently collaborating with:
- Johnson & Johnson
To learn more about ZoBio's services and capabilities and how they can assist your business, please contact ZoBio directly.
- > ZoBio to Attend 14th Annual Drug Discovery Summit 2013
- > Hit to Lead Integrating Fragment Based Drug Discovery with HTS Approaches
- > Fragment Hit Validation
- > Fragment Library Screening
- > NMR - Biophysical Techniques in Drug Discovery
- > CellCentric and ZoBio Partner to Discover Lead Compounds Against Epigenetic Therapeutic Drug Targets
- CRO, CMO, CRAMS & CDMO
- Drug Discovery